DOCSLIB.ORG

Medical Text Indexer (MTI)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Text Indexer (MTI) Medical Text Indexer (MTI) Title + Abstract Phrasex PubMed Noun Phrases Trigram Related Citations MetaMap UMLS concepts Rel. Citations Extract Restrict to MeSH MeSH descr. MeSH Main Headings Clustering & Ranking Ordered list of MeSH Main Headings (Last Updated: Monday, March 13, 2006) Index 1. Introduction............................................................................................................................................................... 3 2. Exclusions................................................................................................................................................................. 4 3. Clustering and Ranking............................................................................................................................................. 6 3.1. Overview of Clustering and Ranking (from BoSC99 report)............................................................................ 6 3.2. UMLS Metathesaurus Files........................................................................................................................... 7 3.2.1. Related Concepts (File = MRREL) ........................................................................................................... 7 3.2.2. Co-occurring Concepts (File = MRCOC).................................................................................................. 8 3.3. Creating the Normalized Frequency Scores for the Co-Occurring Concepts.................................................... 9 3.3.1. Overview ................................................................................................................................................... 9 3.3.2. Detailed Explanation and Example ........................................................................................................... 9 3.4. Calculating TermWeight................................................................................................................................. 10 3.4.1. Tunable and System Parameters.............................................................................................................. 11 3.4.2. Steps Followed in Calculating the TermWeight...................................................................................... 11 3.5. Clustering....................................................................................................................................................... 12 3.5.1. Overview of Steps for Clustering ........................................................................................................... 13 3.5.2. Example of Clustering............................................................................................................................. 14 3.6. Calculating the RankScore.............................................................................................................................. 17 3.6.1. Summary of Steps for Calculating the RankScore .................................................................................. 17 3.6.2. Example of Calculating the RankScore................................................................................................... 18 4. Determining Heading Mapped to (Optional) .......................................................................................................... 20 5. Boosting New Terms .............................................................................................................................................. 21 6. Emphasize Titles..................................................................................................................................................... 21 7. Emphasize HSTAR (Optional) ............................................................................................................................... 21 8. Float Chemicals ...................................................................................................................................................... 22 9. Determine TopN Terms List ................................................................................................................................... 23 10. Senile Plaque/Dental Plaque Disambiguation....................................................................................................... 23 11. Medium Filtering (Optional)................................................................................................................................. 24 12. Validate TopN Terms............................................................................................................................................ 24 13. MH/SH Substitution.............................................................................................................................................. 26 14. Add drug therapy SH......................................................................................................................................... 27 15. Drop physiology & analysis SHs ................................................................................................................... 27 16. Add CheckTags from Text and doAgedReview (Optional).................................................................................. 27 17. Add Geographics from Text (Optional)................................................................................................................ 28 18. Strict Filtering (Optional)...................................................................................................................................... 28 19. Update Chemicals (Optional)................................................................................................................................ 28 20. Add USA CheckTag from Text (Optional)........................................................................................................... 28 21. Display Results ..................................................................................................................................................... 29 21.1. showHMs Display Option............................................................................................................................. 29 MTI Processing Flow Explained i 21.2. limitTitleOnly Display Option ...................................................................................................................... 30 21.3. RSfilterTO Display Option ........................................................................................................................... 30 21.4. limitPTs Display Option................................................................................................................................ 30 21.5. showETs Display Option .............................................................................................................................. 30 Appendix A MTI Exceptions for Medium Filtering ................................................................................................ 33 Appendix B MTI Heuristics for Medium Filtering.................................................................................................. 34 Appendix C CheckTags (2006)................................................................................................................................ 35 Appendix D Bad CheckTags List (BadCTs)............................................................................................................ 35 Appendix E SubHeadings (2006)............................................................................................................................. 36 Appendix F Geographics Lookup & Substitution List (GEOs) ............................................................................... 37 Appendix G MH/SH Lookup & Substitution List (MHSHs)................................................................................... 38 Appendix H MH Exclusion List (MH_Excludes).................................................................................................... 39 Appendix I UMLS Concepts to Exclude List (CUI_Excludes) ............................................................................... 42 Appendix J New MeSH Headings List (NewTerms)............................................................................................... 46 Appendix K Additional US Triggers List (USAtriggers)......................................................................................... 54 Appendix L Lookup Lists ........................................................................................................................................ 55 Appendix M MeSH SubHeading Treecode Triggers List........................................................................................ 78 Appendix N Special Publication Type List.............................................................................................................. 79 List of Equations Equation 1 - TermWeight Formula ............................................................................................................................. 10 Equation 2 - RankScore Formula................................................................................................................................ 17 List of Figures Figure 1: Detailed Medical Text Indexer Process Flow Diagram................................................................................. 3 Figure 2: Picture of how we traverse the item list for clustering
Load more

Recommended publications
  • Clinical Utility Gene Card For: 3-M Syndrome – Update 2013
    European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.156 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg CLINICAL UTILITY GENE CARD UPDATE Clinical utility gene card for: 3-M syndrome – Update 2013 Muriel Holder-Espinasse*,1, Melita Irving1 and Vale´rie Cormier-Daire2 European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.156; published online 31 July 2013 Update to: European Journal of Human Genetics (2011) 19, doi:10.1038/ejhg.2011.32; published online 2 March 2011 1. DISEASE CHARACTERISTICS nonsense and missense mutations c.4333C4T (p.Arg1445*) and 1.1 Name of the disease (synonyms) c.4391A4C (p.His1464Pro), respectively, render CUL7 deficient 3-M syndrome (gloomy face syndrome, dolichospondylic dysplasia). in recruiting ROC1, leading to impaired ubiquitination. OBSL1: microsatellites analysis of the locus (2q35-36.1) in con- 1.2 OMIM# of the disease sanguineous families. OBSL1: microsatellites analysis of the locus 273750. (2q35-36.1) in consanguineous families. Mutations induce non- sense mediated decay. Knockdown of OBSL1 in HEK293 cells 1.3 Name of the analysed genes or DNA/chromosome segments shows the role of this gene in the maintenance of normal levels of CUL7, OBSL1 and CCDC8.1–5 CUL7. Abnormal IGFBP2 andIGFBP5 mRNA levels in two patients with OBSL1 mutations, suggesting that OBSL1 modulates the 1.4 OMIM# of the gene(s) expression of IGFBP proteins. CCDC8: microsatellites analysis 609577 (CUL7), 610991 (OBSL1) and 614145 (CCDC8). at the locus (19q13.2-q13.32). CCDC8, 1-BP DUP, 612G and CCDC8, 1-BP.
    [Show full text]
  • Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest
    Supplementary Online Content Rose SL, Highland J, Karafa MT, Joffe S. Patient advocacy organizations, industry funding, and conflicts of interest. JAMA Intern Med. Published online January 17, 2017. doi:10.1001/jamainternmed.2016.8443 eTable 1. Search Terms Used to Identify Organizations eTable 2. Inclusion and Exclusion Criteria eTable 3. Sensitivity Analysis Comparing Survey Responses of Executive and Non-Executive Respondents of Patient Advocacy Organizations (PAOs) eFigure. Survey This supplementary material has been provided by the authors to give readers additional information about their work. © 2017 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable 1. Search Terms Used to Identify Organizations Aagenaes Syndrome Anoxia Carcinoid Aarskog Syndrome Antiphospholipid Syndrome Carcinoma Aase-Smith Syndrome II Antley-Bixler Syndrome Cardiac Abdominal Cystic Phenotype Cardiogenic Lymphangioma Anxiety Cardiogenic Shock Abdominal Obesity Metabolic Aphasia Cardiomyopathy Syndrome Apraxia Cardiovascular Achondroplasia Arrhythmia Carotid Artery Disease Achromatopsia Arteriosclerosis Celiac Acid Lipase Disease Arthritis Central Cord Syndrome Acoustic Neuroma Asperger Syndrome Cervical Cancer Acquired Hyperostosis Aspergers Chondrodysplasia Punctata Syndrome Asthma Acrocephalosyndactylia Chordoma Astrocytoma Addison Disease Churg-Strauss Syndrome Ataxia ADHD Colon Cancer Atherosclerosis Adie's syndrome Colorectal Cancer Atrial Adrenal Hyperplasia Conduct Disorder Atrial Fibulation
    [Show full text]
  • Glycine Transaminase 1. Identification of The
    SAFETY DATA SHEET glycine transaminase Not for Private Therapeutic Use! 1. Identification of the Substance/preparation and of the company/undertaking 1.1 Identification of the Product: glycine transaminase (EXWM-2880) 1.2 Manufacture/Supplier Identification: Creative Enzymes 45-1 Ramsey Road Shirley, NY 11967, USA Tel: 1-631-562-8517 1-516-512-3133 Fax: 1-631-938-8127 E-mail: [email protected] Website: www.creative-enzymes.com 1.3 Relevant identified uses of the substance or mixture and uses advised against Identified uses: For research use only, not for human or veterinary use. 1.4 Emergency telephone number Emergency Phone #: +1-800-424-9300 (CHEMTREC Within USA and Canada) +1-703-527-3887 (CHEMTREC Outside USA and Canada) 2. Hazards Identification Physical/chemical hazards :n/a Human health hazards: Not specific hazard 3. EC No. / CAS No. EC No.:EC 2.6.1.4 CAS No.: 9032-99-9 4. First Aid Measures 4.1 Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention. 4.2 Ingestion: Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an Unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosentight clothing such as a collar, tie, belt or waistband. Ingestion: Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an Unconscious person. If large quantities of this material are swallowed, call a physician immediately.
    [Show full text]
  • Trim37-Deficient Mice Recapitulate Several Features of the Multi-Organ
    © 2016. Published by The Company of Biologists Ltd | Biology Open (2016) 5, 584-595 doi:10.1242/bio.016246 RESEARCH ARTICLE Trim37-deficient mice recapitulate several features of the multi- organ disorder Mulibrey nanism Kaisa M. Kettunen1,2,3,4, Riitta Karikoski5, Riikka H. Hämäläinen6, Teija T. Toivonen1, Vasily D. Antonenkov7, Natalia Kulesskaya3, Vootele Voikar3, Maarit Hölttä-Vuori8,9, Elina Ikonen8,9, Kirsi Sainio10, Anu Jalanko11, Susann Karlberg12, Niklas Karlberg12, Marita Lipsanen-Nyman12, Jorma Toppari13, Matti Jauhiainen11, J. Kalervo Hiltunen7, Hannu Jalanko14 and Anna-Elina Lehesjoki1,2,3,* ABSTRACT of the human MUL disease and thus provide a good model to study Mulibrey nanism (MUL) is a rare autosomal recessive multi-organ disease pathogenesis related to TRIM37 deficiency, including disorder characterized by severe prenatal-onset growth failure, infertility, non-alcoholic fatty liver disease, cardiomyopathy and infertility, cardiopathy, risk for tumors, fatty liver, and type 2 tumorigenesis. diabetes. MUL is caused by loss-of-function mutations in TRIM37, KEY WORDS: Mulibrey nanism, Infertility, Fatty liver, which encodes an E3 ubiquitin ligase belonging to the tripartite motif Cardiomyopathy, Tumorigenesis, Growth failure (TRIM) protein family and having both peroxisomal and nuclear localization. We describe a congenic Trim37 knock-out mouse INTRODUCTION (Trim37−/−) model for MUL. Trim37−/− mice were viable and had Mulibrey nanism (MUL) is a rare autosomal recessive multi-organ normal weight development until approximately
    [Show full text]
  • Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol
    Jornal de Pediatria ISSN: 0021-7557 ISSN: 1678-4782 Sociedade Brasileira de Pediatria Goudouris, Ekaterini Simões; Segundo, Gesmar Rodrigues Silva; Poli, Cecilia Repercussions of inborn errors of immunity on growth☆ Jornal de Pediatria, vol. 95, no. 1, Suppl., 2019, pp. S49-S58 Sociedade Brasileira de Pediatria DOI: https://doi.org/10.1016/j.jped.2018.11.006 Available in: https://www.redalyc.org/articulo.oa?id=399759353007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative J Pediatr (Rio J). 2019;95(S1):S49---S58 www.jped.com.br REVIEW ARTICLE ଝ Repercussions of inborn errors of immunity on growth a,b,∗ c,d e Ekaterini Simões Goudouris , Gesmar Rodrigues Silva Segundo , Cecilia Poli a Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro, RJ, Brazil b Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Curso de Especializac¸ão em Alergia e Imunologia Clínica, Rio de Janeiro, RJ, Brazil c Universidade Federal de Uberlândia (UFU), Faculdade de Medicina, Departamento de Pediatria, Uberlândia, MG, Brazil d Universidade Federal de Uberlândia (UFU), Hospital das Clínicas, Programa de Residência Médica em Alergia e Imunologia Pediátrica, Uberlândia, MG, Brazil e Universidad del Desarrollo,
    [Show full text]
  • 2021 Western Medical Research Conference
    Abstracts J Investig Med: first published as 10.1136/jim-2021-WRMC on 21 December 2020. Downloaded from Genetics I Purpose of Study Genomic sequencing has identified a growing number of genes associated with developmental brain disorders Concurrent session and revealed the overlapping genetic architecture of autism spectrum disorder (ASD) and intellectual disability (ID). Chil- 8:10 AM dren with ASD are often identified first by psychologists or neurologists and the extent of genetic testing or genetics refer- Friday, January 29, 2021 ral is variable. Applying clinical whole genome sequencing (cWGS) early in the diagnostic process has the potential for timely molecular diagnosis and to circumvent the diagnostic 1 PROSPECTIVE STUDY OF EPILEPSY IN NGLY1 odyssey. Here we report a pilot study of cWGS in a clinical DEFICIENCY cohort of young children with ASD. RJ Levy*, CH Frater, WB Galentine, MR Ruzhnikov. Stanford University School of Medicine, Methods Used Children with ASD and cognitive delays/ID Stanford, CA were referred by neurologists or psychologists at a regional healthcare organization. Medical records were used to classify 10.1136/jim-2021-WRMC.1 probands as 1) ASD/ID or 2) complex ASD (defined as 1 or more major malformations, abnormal head circumference, or Purpose of Study To refine the electroclinical phenotype of dysmorphic features). cWGS was performed using either epilepsy in NGLY1 deficiency via prospective clinical and elec- parent-child trio (n=16) or parent-child-affected sibling (multi- troencephalogram (EEG) findings in an international cohort. plex families; n=3). Variants were classified according to Methods Used We performed prospective phenotyping of 28 ACMG guidelines.
    [Show full text]
  • Constrictive Pericarditis and Primary Amenorrhea with Syndactyly in an Iranian Female: Mulibrey Nanism Syndrome
    TEHRAN HEART CENTER Case Report Constrictive Pericarditis and Primary Amenorrhea with Syndactyly in an Iranian Female: Mulibrey Nanism Syndrome Tahereh Davarpasand, MD, Maryam Sotoudeh Anvari, MD, Mohammad Naderan, MD*, Mohammad Ali Boroumand, MD, Hossein Ahmadi, MD Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Received 25 March 2015; Accepted 10 June 2016 Abstract Mulibrey nanism is a rare autosomal recessive syndrome caused by a mutation in the TRIM37 gene with severe growth retardation and multiple organ involvement. Early diagnosis is important because 50% of the patients develop congestive heart failure owing to constrictive pericarditis, and this condition plays a critical role in the final prognosis. A 37-year-old female patient presented with symptoms of dyspnea on exertion and shortness of breath. She had severe growth failure and craniofacial dysmorphic feature. Cardiac evaluation showed constrictive pericarditis, moderate pulmonary hypertension, and mild pericardial effusion. The patient underwent pericardiectomy, but her thick and adhesive pericardium forced the surgeon to do partial pericardiotomy. Our report underlines the importance of attention to probable Mulibrey nanism when confronting patients with primary amenorrhea, growth retardation, and dysmorphic features. Early cardiac examination is of great significance in the course of the disorder, and patients must be pericardiectomized to relieve the symptoms and increase survival. J Teh Univ Heart Ctr 2016;11(4):187-191 This paper should be cited as: Davarpasand T, Sotoudeh Anvari M, Naderan M, Boroumand MA, Ahmadi H. Constrictive Pericarditis and Primary Amenorrhea with Syndactyly in an Iranian Female: Mulibrey Nanism Syndrome. J Teh Univ Heart Ctr 2016;11(4):187-191.
    [Show full text]
  • Mutations Affecting Cell Fates and Cellular Rearrangements During Gastrulation in Zebrafish
    Development 123, 67-80 67 Printed in Great Britain © The Company of Biologists Limited 1996 DEV3335 Mutations affecting cell fates and cellular rearrangements during gastrulation in zebrafish Lilianna Solnica-Krezel†, Derek L. Stemple, Eliza Mountcastle-Shah, Zehava Rangini‡, Stephan C. F. Neuhauss, Jarema Malicki, Alexander F. Schier§, Didier Y. R. Stainier¶, Fried Zwartkruis**, Salim Abdelilah and Wolfgang Driever* Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, 13th Street, Bldg. 149, Charlestown, MA 02129, USA †Present address: Department of Molecular Biology, Vanderbilt University, Box 1820, Station B, Nashville, TN 37235, USA ‡Present address: Department of Oncology, Sharett Institute, Hadassah Hospital, Jerusalem 91120, Israel §Present address: Skirball Institute of Biomolecular Medicine, NYU Medical Center, 550 First Avenue, New York, NY 10016, USA ¶Present address: School of Medicine, Department of Biochemistry and Biophysics, UCSF, San Francisco, CA 94143-0554, USA **Present address: Laboratory for Physiological Chemistry, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands *Author for correspondence (e-mail: [email protected]) SUMMARY One of the major challenges of developmental biology is mutations in these two groups identify genes necessary for understanding the inductive and morphogenetic processes the formation, maintenance or function of the dorsal that shape the vertebrate embryo. In a large-scale genetic organizer and the ventral signaling pathway, respectively. screen for zygotic effect, embryonic lethal mutations in Mutations in the third group affect primarily cellular zebrafish we have identified 25 mutations that affect spec- rearrangements during gastrulation and have complex ification of cell fates and/or cellular rearrangements during effects on cell fates in the embryo.
    [Show full text]
  • Como As Enzimas Agem?
    O que são enzimas? Catalizadores biológicos - Aceleram reações químicas específicas sem a formação de produtos colaterais PRODUTO SUBSTRATO COMPLEXO SITIO ATIVO ENZIMA SUBSTRATO Características das enzimas 1 - Grande maioria das enzimas são proteínas (algumas moléculas de RNA tem atividade catalítica) 2 - Funcionam em soluções aquosas diluídas, em condições muito suaves de temperatura e pH (mM, pH neutro, 25 a 37oC) Pepsina estômago – pH 2 Enzimas de organismos hipertermófilos (crescem em ambientes quentes) atuam a 95oC 3 - Apresentam alto grau de especificidade por seus reagentes (substratos) Molécula que se liga ao sítio ativo Região da enzima e que vai sofrer onde ocorre a a ação da reação = sítio ativo enzima = substrato 4 - Peso molecular: varia de 12.000 à 1 milhão daltons (Da), são portanto muito grandes quando comparadas ao substrato. 5 - A atividade catalítica das Enzimas depende da integridade de sua conformação protéica nativa – local de atividade catalítica (sitio ativo) Sítio ativo e toda a molécula proporciona um ambiente adequado para ocorrer a reação química desejada sobre o substrato A atividade de algumas enzimas podem depender de outros componentes não proteicos Enzima ativa = Holoenzimas Parte protéica das enzimas + cofator Apoenzima ou apoproteína •Íon inorgânico •Molécula complexa (coenzima) Covalentemente ligados à apoenzima GRUPO PROSTÉTICO COFATORES Elemento com ação complementar ao sitio ativo as enzimas que auxiliam na formação de um ambiente ideal para ocorrer a reação química ou participam diretamente dela
    [Show full text]
  • Genome Mining Reveals the Genus Xanthomonas to Be A
    Royer et al. BMC Genomics 2013, 14:658 http://www.biomedcentral.com/1471-2164/14/658 RESEARCH ARTICLE Open Access Genome mining reveals the genus Xanthomonas to be a promising reservoir for new bioactive non-ribosomally synthesized peptides Monique Royer1, Ralf Koebnik2, Mélanie Marguerettaz1, Valérie Barbe3, Guillaume P Robin2, Chrystelle Brin4, Sébastien Carrere5, Camila Gomez1, Manuela Hügelland6, Ginka H Völler6, Julie Noëll1, Isabelle Pieretti1, Saskia Rausch6, Valérie Verdier2, Stéphane Poussier7, Philippe Rott1, Roderich D Süssmuth6 and Stéphane Cociancich1* Abstract Background: Various bacteria can use non-ribosomal peptide synthesis (NRPS) to produce peptides or other small molecules. Conserved features within the NRPS machinery allow the type, and sometimes even the structure, of the synthesized polypeptide to be predicted. Thus, bacterial genome mining via in silico analyses of NRPS genes offers an attractive opportunity to uncover new bioactive non-ribosomally synthesized peptides. Xanthomonas is a large genus of Gram-negative bacteria that cause disease in hundreds of plant species. To date, the only known small molecule synthesized by NRPS in this genus is albicidin produced by Xanthomonas albilineans. This study aims to estimate the biosynthetic potential of Xanthomonas spp. by in silico analyses of NRPS genes with unknown function recently identified in the sequenced genomes of X. albilineans and related species of Xanthomonas. Results: We performed in silico analyses of NRPS genes present in all published genome sequences of Xanthomonas spp., as well as in unpublished draft genome sequences of Xanthomonas oryzae pv. oryzae strain BAI3 and Xanthomonas spp. strain XaS3. These two latter strains, together with X. albilineans strain GPE PC73 and X.
    [Show full text]
  • Hop Is an Unusual Homeobox Gene That Modulates Cardiac Development
    Cell, Vol. 110, 713–723, September 20, 2002, Copyright 2002 by Cell Press Hop Is an Unusual Homeobox Gene that Modulates Cardiac Development Fabian Chen,1 Hyun Kook,1 Rita Milewski,1 tion and are arranged in the genome in the order in Aaron D. Gitler,1,2 Min Min Lu,1 Jun Li,1 which they are expressed along the axis of the embryo. Ronniel Nazarian,1 Robert Schnepp,1 The “Hox code” represents an important paradigm for Kuangyu Jen,1 Christine Biben,3 Greg Runke,2 the definition of positional identity during embryogene- Joel P. Mackay,5 Jiri Novotny,3 sis in which the specific pattern of overlapping Hox gene Robert J. Schwartz,6 Richard P. Harvey,3,4 expression defines cellular identity. A plethora of non- Mary C. Mullins,2 and Jonathan A. Epstein1,2,7 clustered Hox genes have been identified that are scat- 1Department of Medicine tered throughout the genome and play additional roles 2 Department of Cell and Developmental Biology in cell fate specification in all organs and tissues of the University of Pennsylvania Health System body. Philadelphia, Pennsylvania 19104 Hox genes are defined by the presence of a 60 amino 3 The Victor Chang Cardiac Research Institute acid domain that mediates DNA binding. This domain Darlinghurst, NSW 2010 has been analyzed by NMR spectroscopy and X-ray Australia crystallography either free or in association with DNA 4 Faculties of Medicine and Life Sciences (Kissinger et al., 1990; Qian et al., 1989; Wolberger et University of New South Wales al., 1991). The 60 amino acid homeodomain is capable Kensington, NSW 2051 of adopting a fixed structure in solution composed of Australia three ␣ helices in which the second and third helices 5 School of Molecular and Microbial Biosciences form a helix-turn-helix motif.
    [Show full text]
  • Pig Antibodies
    Pig Antibodies gene_name sku Entry_Name Protein_Names Organism Length Identity CDX‐2 ARP31476_P050 D0V4H7_PIG Caudal type homeobox 2 (Fragment) Sus scrofa (Pig) 147 100.00% CDX‐2 ARP31476_P050 A7MAE3_PIG Caudal type homeobox transcription factor 2 (Fragment) Sus scrofa (Pig) 75 100.00% Tnnt3 ARP51286_P050 Q75NH3_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 271 85.00% Tnnt3 ARP51286_P050 Q75NH2_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 266 85.00% Tnnt3 ARP51286_P050 Q75NH1_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 260 85.00% Tnnt3 ARP51286_P050 Q75NH0_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 250 85.00% Tnnt3 ARP51286_P050 Q75NG8_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 266 85.00% Tnnt3 ARP51286_P050 Q75NG7_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 260 85.00% Tnnt3 ARP51286_P050 Q75NG6_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 250 85.00% Tnnt3 ARP51286_P050 TNNT3_PIG Troponin T, fast skeletal muscle (TnTf) Sus scrofa (Pig) 271 85.00% ORF Names:PANDA_000462 EMBL EFB13877.1OrganismAiluropod High mobility group protein B2 (High mobility group protein a melanoleuca (Giant panda) ARP31939_P050 HMGB2_PIG 2) (HMG‐2) Sus scrofa (Pig) 210 100.00% Agpat5 ARP47429_P050 B8XTR3_PIG 1‐acylglycerol‐3‐phosphate O‐acyltransferase 5 Sus scrofa (Pig) 365 85.00% irf9 ARP31200_P050 Q29390_PIG Transcriptional regulator ISGF3 gamma subunit (Fragment) Sus scrofa (Pig) 57 100.00% irf9 ARP31200_P050 Q0GFA1_PIG Interferon regulatory factor 9 Sus scrofa (Pig)
    [Show full text]